Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 许焕珍女士 (外科学系) |
| 陈林教授 (肿瘤学系) |
| 杨明明教授 (肿瘤学系) |
| 陈德章教授 (肿瘤学系) |
| 吕伟欣教授 (生物医学学院) |
| 马碧如教授 (肿瘤学系) |
| 许焕珍女士 (外科学系) |
| 刘碧玉女士 |
| 黄智?博士 (肿瘤学系) |
全文
| 数位物件识别号 (DOI) http://dx.doi.org/10.1007/s00280-013-2139-4 |
引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/8WOS source URL
其它资讯
摘要RAD001 targets at the mammalian target of rapamycin (mTOR), while TKI-25http://aims.cuhk.edu.hk/converis/portal/Publication/8 is a potent tyrosine kinase inhibitor targeting at fibroblast growth factor receptor, vascular endothelial growth factor receptor, platelet-derived growth factor receptor and c-kit. We aim to study the activity of combined RAD001 and TKI-25http://aims.cuhk.edu.hk/converis/portal/Publication/8 in cell lines and xenograft model of hepatocellular carcinoma (HCC), with reference to the parallel and upstream pathways of Akt-mTOR axis.
着者Chan SL, Wong CH, Lau CPY, Zhou Q, Hui CWC, Lui VWY, Ma BBY, Chan ATC, Yeo W
期刊名称CANCER CHEMOTHERAPY AND PHARMACOLOGY
出版年份2013
月份6
日期1
卷号71
期次6
出版社SPRINGER
页次1417 - 1425
国际标準期刊号0344-5704
语言英式英语
关键词AKT; Hepatocellular carcinoma; mTOR; RAD001; TKI-25http://aims.cuhk.edu.hk/converis/portal/Publication/8
Web of Science 学科类别Oncology; ONCOLOGY; Pharmacology & Pharmacy; PHARMACOLOGY & PHARMACY
